References

Barrott L, Foreman E. Staff sensitisation to therapeutic monoclonal antibodies resulting from workplace exposure: A case report. J Oncol Pharm Pract. 2020; 26:(5)1282-1284 https://doi.org/10.1177/1078155220901750

Blair A, Zheng T, Linos A, Stewart PA, Zhang YW, Cantor KP. Occupation and leukemia: a population-based case-control study in Iowa and Minnesota. Am J Ind Med. 2001; 40:(1)3-14 https://doi.org/10.1002/ajim.1066

Clark C. How can we protect cancer nurses from exposure to hazardous drugs?. Br J Nurs. 2021a; 30:(4)S16-S20 https://doi.org/10.12968/bjon.2021.30.4.S16

Clark C. Helping to protect cancer nurses from exposure to hazardous drugs. Br J Nurs. 2021; 30:(17)S4-S8 https://doi.org/10.12968/bjon.2021.30.17.s4

Crauste-Manciet S, Sessink PJM, Ferrari S, Jomier J-Y, Brossard D. Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Ann Occup Hyg. 2005; 49:(7)619-628 https://doi.org/10.1093/annhyg/mei045

Falck K, Gröhn P, Sorsa M, Vainio H, Heinonen E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet. 1979; 1:(8128)1250-1251 https://doi.org/10.1016/s0140-6736(79)91939-1

Hansen J, Olsen JH. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health. 1994; 20:(1)22-26 https://doi.org/10.5271/sjweh.1433

Lawson CC, Rocheleau CM, Whelan EA Occupational exposures among nurses and risk of spontaneous abortion. Am J Obstet Gynecol. 2012; 206:(4)327.e1-8 https://doi.org/10.1016/j.ajog.2011.12.030

McDiarmid MA, Oliver MS, Roth T, Rogers B, Escalanate C. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med. 2010; 52:(10)1028-1034 https://doi.org/10.1097/JOM.0b013e3181f73ae6

Meade E. Use of closed-system drug transfer devices in the handling and administration of MABs. Br J Nurs. 2015; 24:(16)S21-S27 https://doi.org/10.12968/bjon.2015.24.sup16a.s21

Petralia SA, Dosemeci M, Estes Adams E, Zahm SH. Cancer mortality among women employed in health care occupations in 24 U.S. States, 1984–1993. Am J Indust Med. 1999; 36:(1)159-165

Roussel C, Witt KL, Shaw PB, Connor TH. Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs. Mutat Res Rev Mutat Res. 2019; 781:207-217 https://doi.org/10.1016/j.mrrev.2017.08.002

Skov T, Lynge E, Maarup B, Olsen J, Rørth M, Winthereik H. Risks for physicians handling antineoplastic drugs. Lancet. 1990; 336:(8728) https://doi.org/10.1016/0140-6736(90)93148-i

Skov T, Maarup B, Olsen J, Rørth M, Winthereik H, Lynge E. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992; 49:855-861 https://doi.org/10.1136/oem.49.12.855

Suspiro A, Prista J. Biomarkers of occupational exposure to anticancer drugs: a minireview. Toxicol Lett. 2011; 207:(1)42-52 https://doi.org/10.1016/j.toxlet.2011.08.022

Oncology Nursing Society. Toolkit for safe handling of hazardous drugs for nurses in oncology. 2018. https://www.ons.org/sites/default/files/2018-06/ONS_Safe_Handling_Toolkit_0.pdf (accessed 26 July2022)

Vyas N, Turner A, Clark JM, Sewell GJ. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator. J Oncol Pharm Pract. 2016; 22:(1)10-19 https://doi.org/10.1177/1078155214544993

Wick C, Slawson MH, Jorgenson JA, Tyler LS. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003; 60:(22)2314-2320 https://doi.org/10.1093/ajhp/60.22.2314

Oncology

The need to protect cancer nurses from exposure to hazardous drugs

22 September 2022
Meeting Report
02 September 2022
Volume 31 · Issue 17

Abstract

Freelance medical writer Christine Clark (chris@salt.u-net.com) reports on an online meeting held in May 2022 as part of a series on the risks of exposure to hazardous drugs for nurses working in oncology

On 5 May 2022 Aesculap Academia (the educational arm of B. Braun Medical) held a third webinar to discuss the results of research into the use of closed system transfer devices and the wider issues concerning the risks for nurses of occupational exposure to hazardous drugs. The earlier webinars in this series, held in November 2020 and April 2021, were reported in previous BJN oncology supplements (Clark, 2021a; Clark, 2021b).

An audience of 162 participants from around the world attended an interactive webinar to learn more about cancer nurses' risks of exposure to hazardous drugs.

Opening the meeting Co-Chairs Mark Foulkes (President of the UK Oncology Nursing Society (UKONS) and Nurse Consultant and Lead Cancer Nurse, Royal Berkshire NHS Foundation Trust) and Naomi Clatworthy (Acute Oncology Nurse Consultant, Royal Devon University Healthcare NHS Foundation Trust) commented that the previous two meetings had been strong meetings with lots of audience participation.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content

Register
Or continue by

Signing in with your registered email address